Drug Trial Radar · NCT04529772
A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)
Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
611
Actual
Start
Oct 8, 2020
Primary completion
Feb 22, 2027
Study completion Feb 22, 2027
Sponsor
- Lead sponsor
- Acerta Pharma BVAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- AstraZeneca
- First posted
- Aug 28, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase 3 randomized, double-blind, placebo-controlled, study assessing the efficacy and safety of acalabrutinib plus rituximab,cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) vs placebo plus R-CHOP in subjects ≤75 years of age with previously untreated non-germinal center diffuse large B-cell lymphoma.
Conditions
- Diffuse Large B-Cell Lymphoma
Interventions
acalabrutinibDrug
Investigational Product
placeboDrug
Placebo comparator
PrednisoneDrug
Investigational Product
RituximabDrug
Investigational Product
CyclophosphamideDrug
Investigational Product
VincristineDrug
Investigational Product
DoxorubicinDrug
Investigational Product
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival (PFS) per the Lugano Classification for NHL in Arm A compared to Arm BTime frame: at every single visit up to 60 months
Locations
245 sites in 23 countries. Site status is shown where the registry gives one.
Research Site
Tucson, Arizona
Research Site
Little Rock, Arkansas
Research Site
Irvine, California
Research Site
Aurora, Colorado
Research Site
Norwich, Connecticut
Research Site
Fort Myers, Florida
Research Site
Orlando, Florida
Research Site
St. Petersburg, Florida
Research Site
Tallahassee, Florida
Research Site
West Palm Beach, Florida
Research Site
Fort Wayne, Indiana
Research Site
Des Moines, Iowa
Research Site
Wichita, Kansas
Research Site
Louisville, Kentucky
Research Site
Baltimore, Maryland
Research Site
Grand Rapids, Michigan
Research Site
Minneapolis, Minnesota
Research Site
St Louis, Missouri
Research Site
Albany, New York
Research Site
New York, New York
Research Site
New York, New York
Research Site
Stony Brook, New York
Research Site
Charlotte, North Carolina
Research Site
Winston-Salem, North Carolina
Research Site
Eugene, Oregon
Research Site
Portland, Oregon
Research Site
Philadelphia, Pennsylvania
Research Site
Pittsburgh, Pennsylvania
Research Site
Nashville, Tennessee
Research Site
Fort Sam Houston, Texas
Research Site
Lubbock, Texas
Research Site
Salem, Virginia
Research Site
Adelaide, Australia
Research Site
Camperdown, Australia
Research Site
Darlinghurst, Australia
Research Site
Heidelberg, Australia
Research Site
Hobart, Australia
Research Site
Kogarah, Australia
Research Site
Nedlands, Australia
Research Site
Westmead, Australia
Showing 40 of 245 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.